TY - JOUR
T1 - Determination of doripenem penetration into human prostate tissue and assessment of dosing regimens for prostatitis based on sitespecific pharmacokinetic-pharmacodynamic evaluation
AU - Nakamura, Kogenta
AU - Ikawa, Kazuro
AU - Yamada, Yoshiaki
AU - Arakawa, Maki
AU - Zennami, Kenji
AU - Nishikawa, Genya
AU - Ikeda, Kayo
AU - Morikawa, Norifumi
AU - Honda, Nobuaki
PY - 2012/2
Y1 - 2012/2
N2 - Prostatic hypertrophy patients prophylactically received a 0.5-hour infusion of doripenem (250 or 500 mg) before transurethral resection of the prostate. Doripenem concentrations in plasma and prostate tissue were measured chromatographically, and analysed pharmacokinetically using a three-compartment model. The approved doripenem regimens were assessed based on the time above the minimum inhibitory concentration for bacteria (T>MIC, % of 24 hours), an indicator for antibacterial effects, at the prostate. The prostate tissue/plasma ratios were 17.3% for the maximum drug concentration and 18.7% for the area under the drug concentration-time curve, and they were irrespective of the dose. Against Escherichia coli and Klebsiella species isolates, 500 mg once daily achieved a>90% probability of attaining the bacteriostatic target (20% T>MIC) in prostate tissue, and 500 mg twice daily achieved a>90% probability of attaining the bactericidal target (40% T>MIC) in prostate tissue.
AB - Prostatic hypertrophy patients prophylactically received a 0.5-hour infusion of doripenem (250 or 500 mg) before transurethral resection of the prostate. Doripenem concentrations in plasma and prostate tissue were measured chromatographically, and analysed pharmacokinetically using a three-compartment model. The approved doripenem regimens were assessed based on the time above the minimum inhibitory concentration for bacteria (T>MIC, % of 24 hours), an indicator for antibacterial effects, at the prostate. The prostate tissue/plasma ratios were 17.3% for the maximum drug concentration and 18.7% for the area under the drug concentration-time curve, and they were irrespective of the dose. Against Escherichia coli and Klebsiella species isolates, 500 mg once daily achieved a>90% probability of attaining the bacteriostatic target (20% T>MIC) in prostate tissue, and 500 mg twice daily achieved a>90% probability of attaining the bactericidal target (40% T>MIC) in prostate tissue.
UR - http://www.scopus.com/inward/record.url?scp=84866245942&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84866245942&partnerID=8YFLogxK
U2 - 10.1179/1120009X12Z.0000000007
DO - 10.1179/1120009X12Z.0000000007
M3 - Article
C2 - 22546722
AN - SCOPUS:84866245942
SN - 1120-009X
VL - 24
SP - 32
EP - 37
JO - Journal of Chemotherapy
JF - Journal of Chemotherapy
IS - 1
ER -